GSK3B and Parkinson disease: For example, a LC3-II increase and a LAMP2A decrease have been reported in the substantia nigra of Parkinson’s disease models [53], as well as an alteration of GSK-3β and TDP-43 in some forms of dementia [52], and an impairment of LC3-II and p62 in epilepsy [48].